Article

Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases.

Service d'Anatomie et Cytologie Pathologique et Service d'Urologie, Hôpital La Pitié Salpêtrière, Université Pierre et Marie Curie, Paris, France.
Pathology (Impact Factor: 2.66). 12/2010; 42(7):650-4. DOI: 10.3109/00313025.2010.522173
Source: PubMed

ABSTRACT Micropapillary carcinoma (MPC) of the bladder is an aggressive variant of urothelial carcinoma (UC). It is unknown if any amount of a micropapillary component justifies the diagnosis of MPC. It is also unknown if surface MPC also has aggressive potential.
We studied 72 patients with UC with a micropapillary component in transurethral resections of bladder (TURB) diagnosed between 1998 and 2008. Fifty-seven patients were treated with radical cystectomy. Tumours were classified according to pathological (pT) stage and percentage of MPC (≤ 10%, 10-49%, 50-100%). This was correlated with clinical data and follow up. Significant factors in univariate analysis were entered into a multivariate analysis.
In the TURB specimens, 12 had pTa, 33 pT1 and 27 pT2 tumours with 23% also displaying urothelial carcinoma in situ (CIS). On cystectomy, the MPC component was upstaged in 79% of cases. Twenty-five (35%) patients had metastases at presentation or nodal metastases at cystectomy and 27 patients (38%) died of disease. Mean survival was 17.8 months. Of 12 pTa MPC cases, eight were treated with cystectomy, all displaying invasive carcinoma including five (62%) with pT2-pT4 disease. Three (25%) of these patients died of disease. Seven patients had a MPC component of <10% all of whom had cystectomy. Six of these had invasive carcinoma including two (33%) with pT2-pT4 disease. One (15%) of these patients died of disease. On univariate analysis, the proportion of the MPC component on TURB and pathological stage predicted disease specific survival (p=0.01 and 0.004, respectively), while presence of CIS predicted recurrence (p=0.03). On multivariate analysis, CIS predicted recurrence (p=0.003); however, the proportion of MPC in TURB did not remain significant in predicting disease specific survival. The pathological stage of MPC remained significant in predicting disease specific survival (p=0.04).
Any amount of MPC, even <10% is significant in urothelial carcinoma and should be reported. Surface MPC is associated with invasive carcinoma in most cases which can be high stage. Adequate sampling to include detrusor muscle is crucial in these cases. Associated CIS is important to be recognised and reported as this also impacts on clinical outcome.

0 Bookmarks
 · 
125 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: To assess the impact of micropapillary histological variant on oncological outcome after radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinomas (UTUCs). A French multicenter retrospective study was performed on patients who underwent RNU between 1995 and 2010. Pathological reports were reviewed to identify patients with pure urothelial carcinomas (PUC) and those with micropapillary histological variant (MPC). Uni- and multivariate Cox regression analyses were performed to identify factors predictive of survival. Overall, 519 patients were included and divided into two groups: 480 PUC and 39 MPC. Median follow-up were 28 and 19 months, respectively (p = 0.63). There was no difference between the two groups for gender, age and tumor location (pelvicalyceal or ureteral). MPC was associated with high-stage and high-grade UTUC (p < 0.001 and 0.04). No difference was observed between the two groups for 5-year cancer-specific survival (76.1 vs. 88.2 %; p = 0.54). The 5-year metastasis-free survival was significantly lower in the MPC group (48.9 vs. 73.8 %; p = 0.037). In multivariate analysis, pT stage, lymphovascular invasion, margin status and adjuvant chemotherapy administration were independent predictors of specific survival (p = 0.002; 0.001; 0.02; 0.01), contrary to histological variant (p = 0.94). Micropapillary histological variant was associated with advanced UTUC and reduced metastasis-free survival after RNU. It should be considered as an aggressive tumor and thus be stated in any pathological report after radical surgery.
    World Journal of Urology 08/2013; · 2.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Micropapillary urothelial carcinoma exhibits amplification of the human epidermal growth factor receptor, ERBB2(HER2), and overexpression of the ERBB2 protein product. The clinical significance of this has yet to be established. The objective of this study was to examine ERBB2 amplification and protein expression in micropapillary urothelial carcinoma and stage-matched typical urothelial carcinoma treated by radical cystectomy to assess the frequency of amplification and protein expression, and to determine the association with cancer-specific survival. Pathologic material and data from patients undergoing cystectomy at Mayo Clinic between 1980 and 2008 were reviewed. ERBB2 amplification by fluorescence in situ hybridization (FISH) and protein expression by immunohistochemistry were assessed. Univariate and multivariate Cox proportional hazards regression models were used to evaluate for associations of ERBB2 amplification and protein expression with survival. ERBB2 amplification was identified in 9 (15%) of 61 micropapillary carcinomas compared with 9 (9%) of 100 urothelial carcinomas. In patients with micropapillary carcinoma, ERBB2 amplification was associated with a nearly threefold increased risk of cancer death. ERBB2 amplification (hazard ratio 4.3; P=0.0008) remained associated with an increased risk of death from bladder cancer among patients with micropapillary urothelial carcinoma on multivariate analysis. The association of cancer-specific survival and ERBB2 amplification was not seen in patients with urothelial carcinoma. ERBB2 immunohistochemistry correlated with ERBB2 amplification but there was no association of ERBB2 protein expression and survival. ERBB2 amplification is more frequent in micropapillary urothelial carcinoma than typical urothelial carcinoma, and patients with micropapillary carcinoma who have ERBB2 amplification have worse cancer-specific survival than those who do not. Identification of ERBB2 amplification in micropapillary carcinoma could provide important prognostic information and possibly provide a role for ERBB2 targeted therapy.Modern Pathology advance online publication, 1 November 2013; doi:10.1038/modpathol.2013.201.
    Modern Pathology 11/2013; · 5.25 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Micropapillary variant of urothelial carcinoma (MPUC) showed distinct pathologic features and aggressive behavior. The cytologic findings of MPUC are still indistinct. In this study, we evaluated the cytological findings of MPUC compared with those of high-grade urothelial carcinoma (HGUC). The voided urine cytology of 8 cases of MPUC and 8 cases of HGUC was reviewed. Following cytological parameters were evaluated: cellularity, background, number of small, tight papillary clusters, small acinar structure, scattered single cells, cytoplasmic features, nuclear-to-cytoplasmic ratio, nuclear pleomorphism, nuclear membrane irregularity, hyperchromasia, chromatin pattern and nucleoli. Compared to that of HGUC, cytology of MPUC showed large numbers of small, tight papillary clusters, small acinar structure, few numbers of single cells, and hyperchromatic nuclei. Other parameters were similar between the two groups; both groups showed similar cellularity, dense or vacuolated cytoplasm, moderate to severe nuclear pleomorphism, irregular nuclear membrane, coarse granular chromatin, and small and prominent nucleoli. The urine cytology of MPUCs showed smaller and tighter papillary cell clusters, more small acinar structures, fewer numbers of scattered single cells, and more hyperchromatic nuclei than that of HGUC. These features can help to distinguish MPUC and HGUC and offer an early cytological diagnosis of MPUC.
    The Korean Journal of Pathology 08/2013; 47(4):365-71. · 0.17 Impact Factor

Full-text (2 Sources)

View
50 Downloads
Available from
May 30, 2014